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Osteoarthritis (OA) is characterized by the degradation of articular cartilage and affects 27 
million people in the US. Mesenchymal stem cells (MSCs) are a promising cell source for OA 
therapies because of their immunomodulatory properties and ability to be differentiated along a 
chondrogenic lineage. Traditional chondrogenic differentiation of MSCs relies on using growth 
factors such as TGF-βs, but cells rapidly undergo hypertrophy and are not able to withstand the 
same mechanical load as healthy hyaline cartilage. Decellularized cartilage contains important 
growth factors and extracellular matrix (ECM) proteins to support chondrogenesis at 
physiologically relevant concentrations and may be an alternative or additive to improve 
chondrogenic differentiation. 
The objective of this study was to investigate whether digested cartilage ECM 
incorporation into MSC pellets could improve chondrogenic differentiation alone or in 
combination with exogenous growth factors such as TGF-β1. Porcine articular cartilage was 
decellularized and then digested in pepsin to form an ECM digest. The ECM digest was 
incorporated into 250,000 cell pellets at various concentrations to determine an appropriate dose. 
The ECM digest was then subsequently incorporated into MSCs with and without the addition of 
TGF-β1. The chondrogenic TGF-β1 treated control with no additional ECM was negative for 
glycosaminoglycan (GAG) staining after 21 days in culture, so subsequent experiments 
investigated the role of donor-to-donor variability, passage number, and media composition in 
affecting MSC chondrogenic differentiation. Chondrogenic differentiation of MSC pellets had 
better glycosaminoglycan (GAG) content with TGF-β3 induction compared to TGF-β1, but this 
differentiation was greatly limited in multiple donors with high (>p4) passage number. Future 








 Osteoarthritis (OA) is the degradation of articular cartilage and affects 26.9 million people 
in the US [1]. Healthy articular cartilage is a largely avascular tissue with low cellular density and 
is mainly composed of hyaline cartilage [2]. Hyaline cartilage is characterized by its complex 
extracellular matrix (ECM) of proteins, proteoglycans, and collagens (primarily collagen type II) 
[2]. Collagen is involved in structural support while the negatively charged glycosaminoglycans 
(GAGs) attract water molecules and allow for its absorption and release, giving the tissue its 
compressive mechanical properties. When the mechanical integrity of cartilage is damaged, it is 
no longer able to appropriately shield stress, causing the nerve endings in bone and other tissues 
in the joint capsule to transmit pain. Additionally, inflammatory mediators and local inflammation 
in the synovium (synovitis) are also major driving factors for OA-related pain [3].  
 Chondrocytes are the specialized cells in cartilage that produce and maintain the 
extracellular matrix. They originate from mesenchymal condensations in vivo and a differentiation 
process known as chondrogenesis that is mediated by multiple transcription and growth factors 
[2]. One of the current treatments for cartilage defects, autologous cartilage implantation, involves 
harvesting chondrocytes from a non-load-bearing area, expanding the chondrocytes, then re-
implanting the expanded cells into the defect and sealing with the periosteal flap. Chondrocytes 
can lose their phenotype during proliferation in vitro, however, and undergo dedifferentiation, 
marked by increased secretion of collagen type I (indicative of fibrocartilage formation and inferior 
mechanical properties) [3]. Additionally, the use of the periosteal flap to prevent leakage of grafted 
chondrocytes often stimulates osteophyte formation [4]. This inappropriate tissue formation often 
necessitates total knee arthroplasty [5].  
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 Mesenchymal stem cells (MSCs) may be a promising alternative cell source because they 
can be isolated from adult tissues, have been shown to have immunomodulatory properties [6], 
and can be differentiated along a chondrogenic lineage [7]. Traditional chondrogenic 
differentiation, however, relies on growth factors (TGF-βs and/or BMPs) for induction and 
unfortunately, growth factor mediated chondrogenesis with single or multiple growth factors is 
unable to mimic the complex microenvironment experienced in vivo. Thus, MSCs 
chondrogenically differentiated in vitro rapidly undergo hypertrophy and/or osteogenic 
differentiation, which can lead to the formation of calcified cartilage or bone in vivo rather than 
healthy hyaline cartilage [8]. While growth factors play an important role in mediating 
chondrogenesis in vivo, chondrogenesis is a complex process, involving multiple growth factors 
with specific concentration profiles and multiple ECM components that bind to and release growth 
factors in a concentration dependent manner [9]. There is also a lack of standardization of 
differentiation protocols for MSCs, perhaps because chondrogenesis can be affected by donor-to-
donor variability [10], cell passage number [11], as well as media composition [12]. 
3-D culture formats can improve chondrogenic yield. Hydrogels can be composed of 
multiple biologic or synthetic materials, but many lack the mechanical properties necessary for use 
in vivo [13], or those with appropriate mechanical properties have limited cellular compatibility or 
infiltration [14]. Clustering of cells in micromass and pellet culture with high cell-cell contact is 
believed to mimic the microenvironment experienced by MSCs undergoing mesenchymal 
condensation during embryonic development [15]. Pellet culture has been shown to reduce the rate 
of hypertrophy and increase chondrogenic ECM production with exogenous growth factors, but 
MSC pellets still undergo hypertrophy (typically after 21 to 28 days) [15].  
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Alternatively, decellularized cartilage, cartilage ECM where the cellular components have 
been removed to avoid an immune response, may more closely mimic the natural cartilage 
microenvironment as it is multifactorial, containing multiple growth factors and ECM proteins to 
support chondrogenesis [9]. A previous study found that milled decellularized cartilage ECM (20-
30 nm) incorporation in MSC pellets can upregulate chondrogenic markers (Collagen Type II and 
SOX9), but did not compare ECM incorporation to traditional growth factor mediated 
chondrogenesis or determine if the cells still underwent hypertrophic differentiation [16]. Another 
study found that decellularized cartilage scaffolds (8 mm x 1 mm) supported cell viability and 
proliferation of chondrocytes on the surface of the scaffold, but there was limited cellular 
infiltration and abnormal cell densities due to the low porosity of the scaffold [17].  
Therefore, the objective of this study was to investigate whether digested cartilage ECM 
incorporation into MSC pellets could enhance MSC chondrogenesis and decrease hypertrophy 
alone or in combination with exogenous growth factor(s). Dosing in pellet culture was determined 
using ATDC5 cells, a cell line derived from mouse teratocarcinoma cells and well characterized 
as a chondrogenic cell line that mimics mesenchymal condensation and chondrogenic and 
osteogenic differentiation [18]. Additionally, this study also compares multiple chondrogenic 
differentiation protocols with varying media compositions, donors, and at multiple passage 
numbers to determine appropriate controls to compare for standard chondrogenic differentiation. 
Our hypothesis is that incorporating decellularized cartilage ECM will improve MSC 
chondrogenic differentiation and GAG production and result in less hypertrophic and osteogenic 







Decellularization of cartilage and ECM preparation: Cartilage was isolated from porcine 
articular cartilage and decellularized in a series of chemical and enzymatic washes. The protocol 
is outlined in Table 1 below where we used TrypLE Express, a recombinant form of trypsin and a 
DNase and RNase wash. Decellularization was validated through lack of visible nuclei with 
Hoescht and hematoxylin and eosin (H&E) staining and DNA was quantified using PicoGreen 
Assay (Invitrogen). The isolated cartilage was milled using a Mini-Wiley Mill and then sieved to 
select decellularized pieces between sieve sizes 180 microns and 400 microns. Milled cartilage 
pieces were digested in 10 mg/ml pepsin in 0.01M hydrochloric acid for 48 hours on a stir plate at 
room temperature. After digestion, the ECM degradation products were frozen at -20°C until 
further use. For subsequent studies, ECM degradation products were thawed on ice, pH was 
adjusted to 7.3, and ECM concentration was determined through a BCA protein macro assay 
(Thermo Fisher Scientific).  
         Table 1: Protocol for Decellularization 
 Chemical Time 
1 TryplE Express 6 hours 
2 Type I water 15 min, 9x 
3 70% ethanol 15 hours 
4 3% hydrogen peroxide 15 min 
5 Type I water 15 min, 4x 
6 1% Triton X-100 in EDTA/Trizma 6 hours, 6x 
7 Type I water 15 min, 9x 
8 DNase/RNase Solution 24 hours 
9 Type I water 15 min, 4x 
10 0.1% PAA/4% ethanol 2 hours 




Seeding and culture of ATDC5 cells and pellet culture ECM: ATDC5 cells were seeded at a 
density of 65,000 cells/cm2 and expanded in growth media (Dulbecco’s modified eagle medium/F-
12 (DMEM/F-12) with L-glutamine (Invitrogen) with 1% antibiotic/antimycoctic, 5% fetal bovine 
serum, 10 µl/ml transferrin (Invitrogen), and 3×10-8 M sodium selenite (Sigma)). ECM 
degradation products (0, 10, 20, 30 µg/mL) were added to 2.5 × 105 ATDC5 cells in 500 µl of 
ATDC5 growth media and then centrifuged at 200g for 5 minutes to form MSC-ECM pellets. The 
pellets were then cultured in 15mL conical tubes with partially open caps in an incubator to 
promote gas exchange for 7 days and media was changed every 2-3 days. Pellets were then fixed 
in 10% neutral buffered formalin before manual processing for histology. 
 
Seeding and culture for MSCs with ECM: Human mesenchymal stem cells pooled from two 
donors (Texas A&M) were seeded at a density of 65 cells/cm2 and expanded in MSC growth media 
[Minimum Essential Medium alpha (MEMα) containing 16.3% fetal bovine serum (Atlanta 
Biologicals), 1% antibiotic/antimyoctic and 1% L-glutamine]. 2.5 × 105 MSCs with or without 20 
µg/mL ECM degradation products were centrifuged at 200g for 5 minutes to create MSC pellets 
in 500 µl of Mesenchymal Stem Cell Growth Media. The pellets were then cultured in 15mL 
conical tubes with partially open caps in the incubator to promote gas exchange for up to 21 days 
and media was changed every 2-3 days. Some treatment groups also contained 10ng/ml TGF-β1 
(Peprotech), an exogenous growth factor commonly used for chondrogenic induction [8]. A 
description of the treatment groups and subsequent methods of analysis is shown in Table 2. After 






Table 2: Experimental Design for ECM Incorporation in MSC Pellets 
Group Exogenous Factors ECM Digest Evaluation 
MSCs + TGF-β1 (Positive control) 10ng/mL TGF-β1 - 
PicoGreen (n=6) 
Histology (n=3) 
MSCs  Alone (Negative control) - - 
MSCs + ECM - 20 µg/mL 
MSCs + TGF-β1+ ECM 10ng/mL TGF-β1 20 µg/mL 
 
Comparison of different chondrogenic differentiation protocols: Mesenchymal stem cells 
from three different donors (lot #s 0049, 0055 and 0081) from RoosterBio at two different passages 
(population doubling numbers ~12 and ~15) were each seeded at a density of 3,333 cells/cm2 and 
expanded for 1 week in RoosterBio High Performance Growth Media (KT-001) for a 10 fold 
expansion (to passage doubling numbers ~15 and ~18). 2.5 × 105 MSCs were then centrifuged at 
200g in 15 mL conical tubes for 5 minutes in 500 µl of chondrogenic media (three different 
compositions shown in Table 3) to create MSC pellets. The pellets were then cultured for 21 days 
at 37°C and 5% CO2 with partially open caps to promote gas exchange and media was changed 
every 2-3 days. Pellets were fixed in 10% neutral buffered formalin before manual processing for 
histology. 
Table 3: Chondrogenic Media Formulations 
DMEM with TGF-β1 DMEM with TGF-β3 RoosterBio with TGF-β1 
•  DMEM (Dulbecco’s 
modified Eagle Medium) 
•  1% non essential amino acids 
(NEAA) 
•  1% antibiotic 
•  1% ITS+ 
•  50 µg/ml Ascorbic acid 2-
phosphate (AA2P) 
•  100 nM dexamethasone 
•  10 ng/ml TGF-β1 
•  DMEM (Dulbecco’s 
modified Eagle Medium) 
•  4.7 µg/ml Linoleic-oleic acid 
•  1% antibiotic 
•  1% ITS+ 
•  50 µg/ml Ascorbic acid 2-
phosphate (AA2P) 
•  100 nM dexamathasone 




•  100 nM dexamethasone 




Chondrogenic Differentiation: Histological stains for Safranin-O (SafO), Alcian blue, and 
dimethylmethylene blue (DMMB) assay of the pellets was performed to quantify 
glycosaminoglycan (GAG) content.  
Statistical Analysis: Student’s t-test was used for DNA quantification through PicoGreen® 





RESULTS AND DISCUSSION 
Decellularization Quantification 
DNA quantification with a PicoGreen® Assay (Figure 1)  
indicates effective DNA removal with less than 1 ng 
DNA/mg dry wt. in the decellularized cartilage which is in 
accordance with commercially available ECM scaffolds to 
decrease the risks of an immune response in vivo [19]. 
Histological analysis from hematoxylin and eosin (H&E) 
and Hoescht staining also indicate decellularization through 
to the lack of visible nuclei, but GAGs were also removed 



















Figure 2.	  Histological staining of shows effective decellularization and GAG removal after decellularization. 
H&E and Hoescht staining indicate effective decellularization as seen by a lack of visible nuclei in the decellularized 
samples in comparison to the native cartilage controls. Safranin-O staining indicates GAG removal with 
decellularization through lack of positive (red) staining in the decellularized sample.  
Figure 1. DNA removal in decellularized 
cartilage. DNA is effectively removed 
after decellularization in comparison to 
native articular cartilage as determined by 



















ECM dosing with ATDC5 cells 
 
Decellularized cartilage ECM was incorporated in 250,000 ATDC5 cell pellets in a 
preliminary experiment in order to determine an appropriate dosage that allowed for both cell-cell 
and cell-matrix contact. Pellets with 30µg or more of ECM did not tightly compact during 
centrifugation and pellets fell apart in culture. 20 µg of ECM allowed for cell-cell as well as cell-
ECM interactions and seemed to incorporate well in the pellets and was used for subsequent hMSC 








Figure 3. Decellularized cartilage ECM incorporation in ATDC5 cell pellets. 250,000 ATDC5 cells were 
centrifuged with varying amounts decellularized cartilage ECM digest (0 µg, 10 µg, 20 µg, 30 µg) in 15 ml conical 
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Chondrogenesis with ECM degradation products 
  
 To determine whether cartilage ECM could enhance chondrogenic differentiation, 20 µg 
of ECM degradation products was incorporated in different groups of MSC pellets. Histological 
staining for Safranin O was negative as shown in Figure 4 (all data not shown), which is 
inconsistent with other groups that have shown positive SafO staining after chondrogenic 
differentiation with TGF-β1 [20]. Hematoxylin and Eosin staining was also done for tissue 
structure and morphology. Additionally, Alcian Blue (stains blue for acidic polysaccharides 
including GAGs) staining was performed to qualitatively assess GAG production. As shown in 
Figure 5, the MSCs alone had lighter Alcian Blue staining after 21 days of culture compared to the 
other groups, indicative of less GAG production, but all groups had very little positive staining. 
To investigate whether this inconsistency was due to donor variability, passage number, or media 
formulation, we performed as subsequent study comparing the effect of these factors on 





Figure 4. Limited GAG staining in MSC pellets with cartilage ECM incorporation and/or exogenous growth 
factors. 250,000 Human MSCs were centrifuged with or without 20 µg ECM digest to form MSC pellets. MSCs were 
cultured up to 21 days with exogeneous chondrogenic factor TGF-β1 (10 ng/mL) in growth media and then hstained 
with Safranin-O, which selectively stains sulfated glycosaminogly cans (sGAGs). 
 
  




























































Figure 5. Histological staining of MSC pellets cultured with ECM degradation products and/or exogenous 
growth factors for 21 days. 250,000 Human MSCs were centrifuged with or without 20 µg ECM digest to form 
MSC pellets. MSCs were cultured up to 21 days with exogeneous chondrogenic factor TGF-β1 (10 ng/mL) in 
growth media. Histological samples were stained with hematoxylin & eosin (top) and alcian blue (bottom), which 
stains acidic polysaccharides including sulfated glycosaminoglycans (sGAGs). 
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Comparison of Chondrogenic Differentiation 
 
To determine appropriate controls to compare for standard chondrogenic differentiation, multiple 
chondrogenic differentiation protocols with varying media compositions, donors, and population 
doubling levels were compared. Histological staining for Safranin-O revealed no entirely positive 
pellets in any of the experimental groups but control groups with native porcine cartilage in Figure 
6 below indicate positive staining for GAGs (Figure 6). Groups cultured with serum free media 
containing TGF-β3 and cells from donor lot #0049 had greater GAG production and some places 
with positive staining whereas groups treated with serum containing media (RoosterBio) had the 






Figure 6. Positive staining for GAGs in native porcine cartilage. Positive controls for SafO staining of 




















Figure 7. Comparison of traditional chondrogenesis protocols with varying media compositions, donors and population doubling levels. 250,000 Human 
MSCs from various donors with different passage numbers were centrifuged with to form MSC pellets. MSCs were cultured up to 21 days with three types of 
media containing exogeneous chondrogenic factor TGF-β1 or TGF-β3 (10 ng/mL) in growth media supplemented with or without serum. Histological samples 
were stained with Safranin-O, which selectively stains sulfated glycosaminoglycans (sGAGs).
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Effect of passaging on MSCs 
 No apparent difference in GAG production between passages or population doubling levels 
was seen as the staining seen in Figure 5 was comparable for both tested population doubling levels 
(15 and 18). Extent of chondrogenic differentiation has been shown to decrease with increasing 
passage numbers and lost around the 6th passage [21, 22]. Additionally, MSC markers (CD105 and 
Oct3/4) have also been shown to decrease with increasing passage number [21]. MSCs also show 
characteristics of cellular aging such as actin accumulation [11] as well as reduced hematopoietic 
cytokine synthesis (G-CSF, LIF and SCF) at late passages [11]. Chondrogenic differentiation 
potential is therefore significantly affected with increasing passage number and at late passages 
(>4) can affect the multipotent properties of MSCs [21]. Our results suggest chondrogenic 
differentiation potential is adversely affected after as little at 15 passage doublings, as none of the 
groups tested had true positive staining for GAGs.  
Donor to donor variability 
 All the donors (RoosterBio lot #0049, #0055, #0081) used in this experiment were male 
and between 18-30 years old with >90% expression of MSC surface markers (CD166, CD105, 
CD90, CD73) to indicate stemness. Although the expression of surface markers was similar, there 
was still variability in the chondrogenic potential from each donor. MSCs from lot #0049 produced 
more ECM during expansion, proliferated more slowly, and took longer to trypsinize. This donor 
also had more positive staining for GAGs after 21 days of pellet culture. These differences in 
differentiation potential could result from inherent biological differences between donors. 
Literature has shown that even with similar donor age and expression of biomarkers, there can still 
be dramatic changes in differentiation capacity [10]. Additionally, at late passage numbers (>4), 




 Although serum containing media can promote growth, it is inherently ill-defined as it has 
unidentified components at varying concentrations [23]. Additionally, serum-containing media 
also has a higher risk of contamination, contains xenogeneic proteins that could elicit an immune 
response in patients [23]. Commonly used serum such as fetal bovine serum (FBS) has been shown 
to decrease chondrogenesis and contains unknown inhibitory components [24]. Defined cell 
culture medium can help circumvent some of these drawbacks and has less batch to batch variation. 
Our results indicated that a serum free media had greater GAG production, which is consistent 
with literature that shows serum free media can better conserve chondrogenic differentiation 
potential in comparison to MSCs cultured with serum containing media [12]. 
 TGF-β signaling is an important pathway in traditional chondrogenesis protocols as it 
promotes the production of type II collagen, a major component of cartilage specific ECM. The 
most common isoforms of TGF-β used for chondrogenic differentiation are TGF-β1 and TGF-β3 
[25]. Both isoforms are >75% identical and are structurally similar but have distinct temporal and 
spatial expression in vivo. However, using TGF-β3 in the cell culture media has been proven to 
deposit more GAGs in pellet culture [20]. Our findings are consistent with these previous findings 





CONCLUSIONS AND FUTURE DIRECTION 
The objective of this study was to enhance MSC chondrogenic differentiation using a 
cartilage ECM degradation products in pellet culture. Porcine articular cartilage was effectively 
decellularized and used to make ECM degradation products. A dosing analysis for ECM in pellets 
using ATDC5 cells indicated 20 µg/ml to be adequate for cell-cell and cell-ECM interactions. 
Subsequent MSC pellet culture to test ECM addition used chondrogenic growth factor TGF-β1 
treated MSCs as a control. Our control group was negative for GAG staining after 21 days in 
culture, so subsequent experiments investigated traditional chondrogenic protocols with a focus 
on the role of donor-to-donor variability, passage number, and media composition. Chondrogenic 
differentiation of MSC pellets had better GAG content with TGF-β3 induction compared to TGF-
β1, but this differentiation was greatly limited in multiple donors with high (>p4) passage number.  
Future studies will compare chondrogenic induction with TGF-β3 and/or cartilage ECM of 
human MSCs at earlier passages with more quantitative analysis with DMMB, PCR and ELISAs. 
We will also tag the ECM products with a fluorescent dye to differentiate between the ECM 
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